Cancer diagnostics and monitoring
3 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- TECOBIOSCIENCES GMBH
German biotech SME specializing in cancer diagnostics, medical imaging nanomaterials, and biosafety assays through EU research mobility partnerships.
“Sustained involvement across PRISAR, ISPIC, CANCER, PRISAR2, and cONCReTE — covering image-guided surgery, immunotherapy, active surveillance, and RNA therapeutics for cancer.”
PrimarySMEDE9 projects - PROGREDUM GMBH
German SME participating in biomedical staff exchange networks focused on cancer therapy, medical imaging, and RNA therapeutics.
“PRISAR2 (rectal cancer surveillance), CANCER (postoperative immunotherapy), and cONCReTE (RNA cancer therapeutics) all address different aspects of cancer management.”
PrimarySMEDE5 projects - TACIT BIO INNOVATION LIMITED
UK biomedical company participating in cancer research exchange networks, focused on RNA therapeutics and non-surgical cancer monitoring.
“PRISAR2 focuses on proactive cancer monitoring as alternative to surgery; cONCReTE develops RNA-based cancer therapeutics — both active since 2020.”
PrimaryUK3 projects